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A B S T R A C T
Background: TV-1380 is a rationally mutated, human BChE fused to human serum albumin that has high hy-
drolytic enzymatic activity against cocaine and as well as an extended elimination half-life.
Objective: The present studies examined the safety of TV-1380 and its protective eﬀect when given to monkeys
alone or concomitantly with cocaine and ethanol.
Methods: A set of studies was conducted in monkeys with TV-1380. The parameters tested included telemetric
assessment of cardiovascular parameters, clinical pathology, plasma analysis of cardiac troponin I, ex-vivo
analyses of cocaethylene and PK analysis of serum concentrations of TV-1380, cocaine and its metabolites, and
histopathological examinations.
Results: TV-1380 treatment in monkeys was well tolerated. TV-1380 pretreatment prior to cocaine signiﬁcantly
attenuated the cardiac eﬀects of cocaine and reduced cocaine-induced elevations in serum cardiac troponin I.
TV-1380 changed the metabolic fate of cocaine resulting in decreased exposure to benzoylecgonine, while in-
creasing the exposure to ecgonine methyl ester in plasma.TV-1380 reduced the plasma levels of the toxic me-
tabolite cocaethylene formed after co-administration of ethanol and cocaine.
Conclusion: The results of this study demonstrate that TV-1380 not only accelerates the elimination of cocaine,
but also protects the treated animal from the cardiac eﬀects of cocaine, and inhibits the formation of the toxic
cocaethylene metabolite when cocaine is given together with ethanol, supporting further clinical development of
modiﬁed BChE products as possible treatments for cocaine abuse.
1. Introduction
Cocaine use impacted the lives of 18 million people in 2014, as
reported by the United Nations Oﬃce on Drugs and Crime in 2016
(UNODC, 2016). In addition to the known hazards of cocaine use and
abuse, cocaine can cause cardiovascular pathologies, including myo-
cardial infarction, heart failure, arrhythmias, aortic dissection, and
endocarditis (Rezkalla and Kloner, 2007; Stankowski et al., 2015).
Presently, there are no approved pharmaceuticals to treat cocaine
addiction (Shorter et al., 2015). A potential approach to treatment of
cocaine addiction is the administration of rational, mutagenic, hydro-
lytic enzymes that can accelerate cocaine metabolism (Sun et al., 2002).
Butyrylcholinesterase (BChE) is the main endogenous enzyme that hy-
drolyses cocaine to its inactive metabolites, ecgonine methyl ester and
benzoic acid in plasma (Xie et al., 1999; Inaba et al., 1978). Carbox-
ylesterase-1 (CE1) is active in the liver and hydrolyzes cocaine to pro-
duce benzoylecgonine and methanol. Oxidative enzymes in the liver
can also metabolize cocaine to produce norcocaine, which can be
further metabolized by BChE hydrolysis to norecogonine methyl ester
(Fig. 1). Cocaine elimination can be enhanced by using exogenously
added BChE. This treatment is well tolerated (Morishima et al., 1999).
However, because its half-life is short and it has low catalytic activity
on cocaine, endogenous BChE was not developed as a treatment for
cocaine addiction. TV-1380 (AlbuBChE/Albu-CocH), was developed as
a quadruple mutant form of human BChE (A199S/S287G/A328W/
Y332G) with approximately 1000x fold higher hydrolytic activity (Pan
et al., 2005) against cocaine than BChE, and a longer half-life due to its
fusion at its carboxy- terminus with recombinant human serum albumin
(HAS; Schlindler et al., 2013; Gao et al., 2008).
Clinical trials for TV-1380 as a treatment for cocaine dependence
and overdose were initiated when pretreatment with TV-1380 was
found to accelerate cocaine metabolism in monkeys (Schlindler et al.,
2013), attenuate the toxic eﬀects of cocaine, prevent convulsions, and
prevent priming-induced relapse to cocaine use in rats (Brimijoin et al.,
2008). In 2016, the clinical development of TV-1380 was halted after a
phase II clinical trial did not result in an enhanced rate of abstinence
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among the treated users (Gilgun-Sherki et al., 2016).
Part of the development program of TV-1380 involved assessing its
safety in monkeys, and in the course of these studies, it found that TV-
1380 may have beneﬁts as a treatment to reduce the cardiotoxic eﬀects
that can occur with cocaine abuse, in particular when it is consumed in
combination with alcohol.
Thus, the studies described herein are investigations of the potential
of TV-1380 to reduce cocaine-induced changes of cardiodynamic
parameters. First, we measured cardiac safety parameters in treated
cynomolgus monkeys and the blood concentrations of cocaine and its
metabolites in the presence or absence of TV-1380. Secondly, we in-
vestigated the interaction with ethanol, since a vast majority of cocaine
users consume cocaine in combination with alcohol (European
Monitoring Centre for Drugs and Drug Addiction, 2009) because of a
more intense feeling of ‘high' beyond that perceived with either drug
alone (Pennings et al., 2002). Alcohol is known to react with cocaine to
produce cocaethylene, an active cytotoxic metabolite (Julien et al.,
2011) that is implicated in the cardiotoxicity of cocaine (Wilson et al.,
2001; McCance-Katz et al., 1998). Cocaethylene has a similar psy-
choactive eﬀect as cocaine, but is associated with liver damage, seizures
and the risk of immediate death is known to be 18–25 times higher than
with cocaine alone (Andrews, 1997). To address this complication, we
have tested the eﬀect of TV-1380 on the generation of cocaethylene in
monkeys treated with cocaine and ethanol.
2. Materials and methods
2.1. Animal husbandry
The animal studies complied with Good Laboratory Practice (GLP)
and were carried out at AVANZA (Gaithersburg, MD, USA) and MPI
Research, Inc. (Mattawan, MI, USA) laboratories in cynomolgus mon-
keys (Macaca fascicularis), originally supplied by Harlan or Alpha
Genesis at the age range of 3–8 years old. The animals had unrestricted
access to water and were fed a daily amount of diet (Lab Diet) sup-
plemented with fresh fruits, vegetables, and other enrichment foods. All
animals were housed in a humidity-and temperature-controlled room.
The animal care facilities were fully accredited by AAALAC
International and all experiments were approved by the Institutional
Animal Care and Use Committee (IACUC). Male monkeys were housed
individually, and female monkeys were pair-housed in stainless steel
double-sized cages.
2.2. Study designs
2.2.1. Subchronic toxicology study in monkeys
Twenty male and twenty female sexually mature cynomolgus
monkeys were divided into four groups, a control group (n=6/gender)
that received the vehicle (formulation buﬀer) and three groups that
received TV-1380; 10mg/kg (n=4/gender), 20mg/kg (n=4/gender)
and 50mg/kg (n=6/gender). Animals were administered the for-
mulations twice weekly for 13 weeks (26 doses) via two bolus in-
tramuscular (IM) injections. In the high dose and control groups, 2
animals per sex were maintained for an oﬀ treatment/recovery period
of 4 weeks. All animals were observed for morbidity, mortality, clinical
signs, clinical pathology evaluation, body weights, food and water
consumption. At termination, necropsy examinations were performed.
2.2.2. Cardiovascular and respiratory safety study
Six male and six female animals with implanted telemetrized units
were assigned to 4 treatment groups. Group 1 (n=3/gender) animals
were injected twice with the vehicle (formulation buﬀer), once on Day
−8 to measure baseline cardiovascular and ECG parameters, and once
on Day−4 to measure baseline respiration parameters. On day 1 of the
study, TV-1380 was administered IM at a dose level of 15mg/kg and
cardiovascular and ECG parameters were assessed. Treatment with TV-
1380 was repeated on Day 4 and respiration endpoints were followed
(Table 1). The second phase of the study started after Group 1 was
completed. Group 2 (n= 3/gender) monkeys were used to test the in-
teraction of TV-1380 and cocaine. Baseline of the cardiovascular
parameters was established at Day−4. On Day 1, animals were treated
with vehicle and with cocaine alone at 1mg/kg by IV injection. On Day
Fig. 1. Metabolic pathways for cocaine elimination in humans. With permission from Xie et al. (1999). Molecular Pharmacology 55, 83–91.
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4, the monkeys were ﬁrst dosed with TV-1380 IM 15mg/kg, followed
three hours later by IV cocaine 1mg/kg administration. Cardiovascular
endpoints were measured after each treatment.
2.2.3. Cocaine metabolism study
A total of 11 naïve, adult male cynomolgus monkeys were divided
into four dose groups: A control group (n=2) that only received a
single IV dose of cocaine (1mg/kg) and three dose groups (n=3) that
were pre-treated with a single administration of TV-1380 (0.2, 1 or
5mg/kg) by the IM route followed by administration of 1mg/kg co-
caine IV dose repeated ﬁve consecutive times, at 2, 48, 96, 120, and
240 h after TV-1380 administration.
2.2.4. Study on the eﬀect of TV-1380 on cocaine metabolism in the
presence of ethanol
Four animals were used in this study in several phases (Table 2).
Between each phase of treatment, a seven-day washout period was in-
troduced. In the ﬁrst phase, the four animals were treated with vehicle
(formulation buﬀer) and three hours later were administered ethanol
(1.5 g/kg) orally, followed by cocaine administration 30min later. In
Phase 2 of the study, which was performed one week later, TV-1380
(5mg/kg) was given ﬁrst to the four monkeys, followed three hours
later by an oral administration of ethanol (1.5 g/kg) and then cocaine
(IV, 1mg/kg) which was given 30min post ethanol treatment. In Phase
3, a similar sequence of TV-1380 pretreatment followed by ethanol and
cocaine administration as in Phase 2 was given to the animals, but with
a lower dose of ethanol (0.5 mg/kg rather than 1.5 mg/kg). Blood
samples for determination of the plasma concentrations of cocaine and
its metabolites were collected at pre-dose, 5, 10, 15, 20, 30, 40, 60, and
120min following completion of the IV cocaine dose.
2.3. Procedures
2.3.1. Cardiovascular and respiratory examinations
Monkeys were implanted with a sterile telemetry unit (Data Science
International (DSI) Telemetry System DataQuest A.R.T. 3.1. St. Paul,
MN) and a vascular access port (VAP). Telemetry units were implanted
in the abdomen of each animal. Animals underwent at least a 14-day-
post-operative recovery period prior to initiation of dosing. The tele-
metry unit signals were veriﬁed for an extended period of time to en-
sure stability. Heart rate, QT, PR, RR, and QRS intervals were measured
from the representative electrocardiogram (ECG) waveform. The RR
interval was calculated and reported from the measured heart rate. QTc
was calculated based on QT interval and heart rate (Spence’s correc-
tion). The rate pressure product was calculated as the heart rate mul-
tiplied by the systolic pressure.
2.3.2. Measurement of respiration
Respiration rate, saturated blood oxygen (SpO2) and end-tidal CO2
(ETCO2) were measured on speciﬁc days (noted as Respiratory). Data
was collected with a Surgivet V9004 Capnograph (Waukesha, WI).
Respiratory rates were manually recorded.
2.3.3. Histopathology
Microscopic examination of ﬁxed hematoxylin and eosin-stained
paraﬃn sections was performed on sections of tissues from all animals
at the end of the dosing period in the sub-chronic 13 weeks toxicity
study.
2.3.4. Measurement of cardiac troponin I in plasma
Serum cardiac troponin I (cTnI) evaluations were conducted on
animals in the cocaine metabolism in combination with ethanol study.
Blood samples were collected from the femoral vein in alert animals
and transferred into standard tubes. Serum analysis of cTnI was con-
ducted at Antech Labs (USA). Serum was collected and analyzed using a
solid phase chemiluminescent immunoassay method (Siemens
Diagnostics Imulite System).
2.3.5. Ex-vivo catalytic activity of TV-1380 on cocaethylene compared to
cocaine
Human serum from healthy donors was spiked with diﬀerent
amounts of TV-1380 and then diluted 1/100 in PBS (Table 3). The
spiked material was incubated with cocaine or cocaethylene for various
time intervals. A liquid chromatography tandem mass spectrometry
(LC/MS/MS) method was used to determine substrate concentrations at
each time point. Km and kcat were calculated and the ratio kcat/Km
was used to compare the eﬃcacy of TV-1380 activity on both sub-
strates. The study was conducted at the Tandem Laboratories (Salt Lake
City, UT, USA).
2.3.6. Analysis of cocaine, cocaine metabolites or TV-1380 levels in plasma
and pharmacokinetic evaluation
Analysis of serum cocaine and its metabolites: benzoylecgonine,
Table 1
Cardiovascular and respiratory safety study design.
Group
Number
Number
Animals
Study day Treatment Dose
Level
(mg/kg)
Type of Data
Collection
1 3 per
gender
−8 Vehicle 0 Cardiovascular
−4 Vehicle 0 Respiratory
1 TV-1380 15 Cardiovascular
4 TV-1380 15 Respiratory
2 3 per
gender
−4 Vehicle 0 Cardiovascular
Saline 0
1 Vehicle 0 Cardiovascular
Cocaine 1
4 TV-1380 15 Cardiovascular
Cocaine 1
Table 2
Study design of cocaine metabolism in combination with ethanol in monkeys.
Phase Treatment combination Route of Administration Study time
Phase 1 Vehicle (0mg/kg) IM Week 1
+ Ethanol (1.5 g/kg) PO
+ Cocaine (1mg/kg) IV
Phase 2 TV-1380 (5mg/kg) IM Week 2
+ Ethanol (1.5 g/kg) PO
+ Cocaine (1mg/kg) IV
Phase 3 TV-1380 (5mg/kg) IM Week 3
+ Ethanol (0.5 g/kg) PO
+ Cocaine (1mg/kg) IV
IM – intramuscular PO – oral gavage IV – intravenous.
Table 3
Kinetic parameters determined in vitro for (−)-cocaine and cocaethylene hy-
drolyses catalyzed by TV-1380 in comparison with published data on wildtype
BChE.
TV-1380 Wild type
-BChE
Reference for
Wild type
Cocaine Km (μM) 4.75 4.5 Sun et al.
(2002)
kcat (min−1) 1499 4.1
kcat/Km
(M−1 min−1)
3.26× 108 9.11×105
Cocaethylene Km (μM) 11.1 7.5 Hou et al.
(2014)
kcat (min−1) 7.97 3.3
kcat/Km
(M−1 min−1)
7.3×107 4.40×105
Mean of two experiments.
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cocaethylene, ecgonine methyl ester, norcocaine, and norecgonine
methyl ester was performed using validated LC/MS/MS methods
(Tandem Labs USA, West Trenton, NJ). For the cocaine, benzoylecgo-
nine and ecgonine methyl ester methods, the lower limits of quantiﬁ-
cation were 1.0 ng/mL and upper limits of quantiﬁcation were
1000–10000 ng/mL. For cocaethylene, the lower limit of quantiﬁcation
was 0.050 ng/mL and upper limit of quantiﬁcation was 50 ng/mL.
Serum sample analysis for TV-1380 concentration was conducted using
a validated ELISA method. The WinNonlin Professional software (ver-
sion 4.0.1) was used to calculate pharmacokinetic parameters by a non-
compartmental modeling of IV bolus for cocaine and extravascular
input modeling was applied for the metabolites. If there were fewer
than three data points in the terminal phase of the plasma concentra-
tion curve, the terminal phase half-life and PK parameters derived from
the half-life were not calculated for that proﬁle.
2.4. Drugs
TV-1380 (AlbuBChE/Albu-CocH) was manufactured and supplied as
a lyophilized material by Teva Pharmaceutical (USA) and was recon-
stituted with sterile water for injection to ﬁnal concentrations of 30 or
100mg/mL. The reconstituted solution was then diluted with buﬀer
(10mM sodium phosphate, 200mM mannitol, 60 mM trehalose dihy-
drate, 0.01% polysorbate 80 or 50mM sodium phosphate, 115mM
mannitol, 35mM trehalose, and 0.03% (w/v) polysorbate 80, pH 7.2)
and given to the monkeys by intramuscular injection in a volume of
0.167mL/kg or 0.5 mL/kg. Cocaine (Mallinckrodt, St. Louis, MO,USA)
was dissolved in saline. Cocaine was injected by an intravenous infusion
in volume of 0.2 mL/kg or 1mL/kg. Ethanol (Spectrum Chemical Labs,
New Brunswick, NJ, USA) was diluted from a stock of 95% in distilled
water and given to the animals by gavage at a dose volume of 3.75mL/
kg at dose levels concentrations of 0.5 and 1.5 g/kg.
2.5. Statistical analysis
Repeated measures mixed models with treatment groups, time and
sex as ﬁxed eﬀects and animals ID as random eﬀect were employed to
see the eﬀect of cocaine administration on cardiovascular events, and
separately, the eﬀect of TV-1380 administration on cocaine's eﬀect on
cardiovascular events. The eﬀects of TV-1380 on the pharmacokinetic
exposure parameter (AUC0-t) of cocaine and its metabolites (benzyl-
ecognine and ecognine methyl-ester) and the respiratory parameters
(sPO2, ETCO2 and respiration rate) were analyzed using a two-way
ANOVA with a nested Dunnett test.
Inferential analyses were conducted using ®JMP Statistical
Discovery software version 13.1.0 from ®SAS Institute Inc. Cary, NC.
Additional descriptive statistics such as mean, standard error (SE), and
% coeﬃcient of variation (%CV) were calculated using Excel
(Microsoft).
3. Results
Studies described herein are part of the preclinical safety package
that was carried out to support clinical trials of TV-1380 in healthy
volunteers (Cohen-Barak et al., 2015) and in cocaine users (Shram
et al., 2015; Gilgun-Sherki et al., 2016).
3.1. Sub-chronic 13-week toxicity study of TV-1380 in cynomolgus
monkeys
Treatment of monkeys with TV-1380 at doses up to 50mg/kg twice
a week for 13 weeks was well tolerated and all animals survived the
study without showing treatment-related adverse clinical signs, changes
in food consumption, or eﬀects on body weight and body weight gain.
Hematological, blood and urine chemistry investigations conducted at
the end of dosing period demonstrated no treatment related eﬀects in
either sex at any dose level.
Histopathological examination revealed ﬁndings of minimal se-
verity at the injection sites and the adjacent sciatic nerve without dose
dependency. The treatment-related ﬁndings at the injection sites con-
sisted of perivascular inﬁltrates of either lymphocytes or mixed leuko-
cytes and a low degree of lymphoid inﬁltration. There was no asso-
ciated vascular degeneration or necrosis. The ﬁndings in the sciatic
nerve consisted of perivascular lymphoid inﬁltrates in the loose con-
nective tissue surrounding the sciatic nerve in males at all doses and
females at 10mg/kg and 20mg/kg. There was no cellular damage at
the sciatic nerve itself. This is an expected ﬁnding when proteins are
injected and is common to many other injected proteins (Engelhardt,
2008). These ﬁndings showed a trend for recovery following a 28 day of
washout and were considered non-adverse.
3.2. Cardiovascular and respiratory investigations in cynomolgus monkeys
The eﬀect of TV-1380 on the cardiovascular and respiratory systems
in monkeys was tested in the presence and absence of cocaine in six
male and six female monkeys. The animals were divided into two
groups, which were administered TV-1380 consecutively according to
the sequence described in Table 1. Treatment with TV-1380 alone at
15mg/kg in both Group 1 and 2 had no eﬀect on respiration rate,
oxygen saturation (SpO2), or End Tidal CO2 (ETCO2).
As shown in Fig. 2, the administration of cocaine at 1mg/kg by IV
injection resulted in anincrease in body temperature (p < 0.01), which
peaked at about 60min after dosing (maximum change of approxi-
mately 0.5 °C) and in an immediate increase in heart rate (maximum
change of 80 bpm), blood pressure (maximum change of 40mmHg in
systolic pressure and 31mmHg in diastolic pressure) and mean arterial
pressure (maximum change of 35mmHg) (all p < 0.01). The (heart)
rate pressure product was similarly aﬀected (maximum change of
21,976 bpm*mmHg), all of which peaked within 5–10min (Fig. 2).
These eﬀects were greater than the changes in heart rate and pressure
that occurred after vehicle and are attributed to the normal response to
manipulation.
Pretreatment of monkeys with TV-1380 at 15mg/kg, 3 h before
cocaine administration attenuated the eﬀects induced by cocaine alone
(Fig. 2; all p < 0.01). The most notable eﬀects of TV-1380 were re-
duction of body temperature (maximum change of−0.5 °C), heart rate
(maximum change of 35 bpm) and heart rate-pressure product (max-
imum change of 14,438 bpm*mmHg). The heart rate, systolic and
diastolic pressure, mean arterial pressure, and the rate-pressure product
in TV-1380 pretreated animals also returned to baseline faster
(16–32min) than in the animals that received cocaine alone
(80–120min).
No cardiac arrhythmias, no abnormal T wave changes and no atrial
or ventricular arrhythmias were observed in any animal either with
cocaine alone, TV-1380 alone or in combination. All QT intervals in the
treated animals were within normal limits.
3.3. Cocaine metabolism of TV-1380 treated cynomolgus monkeys
Analysis of plasma in cocaine treated monkeys pretreated with
diﬀerent doses of TV-1380 indicated that TV-1380 accelerates the
elimination of cocaine as a function of TV-1380 dose (Fig. 3A). This
eﬀect was most pronounced and statistically signiﬁcant in the ﬁrst few
hours after TV-1380 pretreatment and diminished as time progressed,
consistent with the elimination of TV-1380 from the plasma (Fig. 4),
and by 240 h post-TV-1380 administration the hydrolytic eﬀect of TV-
1380 was no longer apparent. The elimination of cocaine under the
inﬂuence of TV-1380 was also associated with reduced plasma levels of
benzoylecognine, which is the metabolite formed by liver carbox-
ypeptidase (Fig. 3B), suggesting a shift towards the oﬀ-liver BChE
pathway. Reciprocally, the plasma levels of the BChE dependent co-
caine metabolite, ecgonine methyl ester, were increased following TV-
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1380 (Fig. 3C), reﬂecting the enhanced metabolism by this pathway.
TV-1380 pharmacokinetic proﬁle was characterized at all dose le-
vels (Fig. 4). All animals had measurable TV-1380 concentrations. TV-
1380 exposure increased with increasing dose. TV–1380 Tmax ranged
from 3 h (for 0.2 and 1mg/kg dose) to 6 h (for the 5mg/kg dose).
Terminal elimination (t½) of TV-1380 increased from 31 to 62 h with
increasing TV-1380 dose. The eﬀect of TV-1380 on cocaine metabolism
was both time and dose dependent.
Fig. 2. Cardiovascular response to cocaine, TV-1380 or combination in treated cynomolgus monkeys. Mean (SE) responses from males and females monkeys (n=3/
gender) are shown: mean body temperature (°C) (A), mean heart rate (beats per minute) (B), mean systolic and diastolic blood pressure (mmHg) (C), mean arterial
blood pressure (mmHg) (D), rate pressure product (beats per minute x mmHg) (E). The red arrow represents the time of injection of TV-1380 or formulation buﬀer.
The black arrow represents the start of saline or cocaine injection. Asterisks ** indicate statistically signiﬁcant (p < 0.01) diﬀerences in cardiovascular events due to
the administration of TV-1380 to animals treated with cocaine (purple line) versus animals treated with cocaine and no treatment with TV-1380 (blue line). (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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3.4. Ex vivo catalytic activity of TV-1380 on cocaethylene compared to
cocaine
To investigate the eﬀect of TV1380 on cocaethylene metabolism,
human serum was spiked with diﬀerent amounts of TV-1380 and in-
cubated with either cocaine or cocaethylene as substrates. The kinetic
parameters of the enzymatic reactions (Table 3) indicate that TV1380 is
considerably more potent in the hydrolysis of cocaine than in the hy-
drolysis of cocaethylene, with kcat average values of 1499 (min−1) and
7.97 (min−1) respectively. Km values were similar, but slightly higher
for the cocaethylene substrate. The kcat/Km values for these two re-
actions were calculated as 3.26× 108and 7.3×107(M−1 min−1), re-
spectively. These catalytic values are two and three orders of magnitude
higher for both substrates than the values published for the wild type
enzyme (Hou et al., 2014; Sun et al., 2002) and indicate that TV-1380 is
eﬀective as a hydrolytic enzyme for cocaethylene.
3.5. Cocaine metabolism in combination with ethanol in TV-1380 treated
cynomolgus monkeys
In light of the noted catalytic activity of TV-1380 on cocaethylene as
seen in our in-vitro study, we have examined if TV-1380 can eﬀectively
metabolize cocaethylene in vivo in monkeys. To this end, we char-
acterized the pharmacokinetic proﬁles of cocaine and its metabolites
when cocaine and ethanol are given with and without TV-1380 pre-
treatment. Four adult male cynomolgus monkeys were treated con-
secutively in 3 study phases, separated by a washout period according
to the schedule described in Table 2.
The results of this experiment are illustrated in Fig. 5, panels A-D.
The plasma concentrations of cocaine (Panel A) demonstrate that the
IM administration of 5mg/kg TV-1380 to the monkey completely
eliminated the exposure to cocaine regardless of the levels of co-ad-
ministered ethanol (either 1.5 g/kg or 0.5 g/kg). TV-1380 also com-
pletely eliminated the exposure to the two metabolites; cocaethylene
(Panel B) and benzoylecognine (Panel C). In contrast, the plasma levels
of ecgonine methyl ester (Panel D) were markedly increased in mon-
keys which received TV-1380 prior to cocaine and alcohol regardless of
the level of the alcohol dose (0.5 or 1.5 g/kg). The markedly reduced
exposure to both benzoylecognine and cocaethylene following TV-1380
pretreatment indicates that in the presence of TV-1380, the hydrolysis
of cocaine to benzoylecognine by hCE1 (Brzezinski et al., 1997) car-
boxylesterase is shifted towards the formation of ecognine methyl ester.
Since the formation of cocaethylene is critically linked to the hydrolysis
by hCE1 carboxylesterases (Farre et al., 1997; Parker and Laziure,
2010), the TV-1380 shift in cocaine metabolism diminished the pro-
duction of cocaethylene under the study conditions. The data also show
that the presence of alcohol does not modify the catalytic eﬃciency of
TV-1380.
Fig. 3. Plasma exposure of cocaine and its metabolites following TV-1380
treatment in male cynomolgus monkeys. Mean (SE) exposure of cocaine AUC(0-
t) (A) benzoylecgonine AUC(0-t) (B) ecgonine methyl ester AUC(0-t) (C) fol-
lowing 1mg/kg IV cocaine dose following pretreatment with control (n=2) or
TV-1380 various doses (n=3). Pretreatment with TV-1380 occurred at 2, 48,
96, 120, and 240 h prior to cocaine administration. Signiﬁcant diﬀerences in
the AUC0-t of cocaine and metabolites benzoylecgonine and ecgonine methyl
ester between no TV-1380 and diﬀerent doses of TV-1380 (0.2, 1, and 5mg/kg)
are indicated with asterisks; * p < 0.05, ** p < 0.01.
Fig. 4. Serum concentration TV-1380 (ng/mL) vs. time (hour) proﬁle in male
cynomolgus monkeys. Average exposure following a single intramuscular ad-
ministration of TV-1380 dose 0.2, 1 or 5 mg/kg/animal.
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3.6. Measurement of plasma levels of cardiac tropinin I
Cardiac troponin I (cTnI) concentration in peripheral blood is a
known biomarker for cardiotoxicity (Wallace et al., 2004). In our in-
vestigation of the metabolic fate of cocaine in the presence of alcohol
and TV-1380, serum samples were also analyzed for cTnl (Fig. 6). The
combination of ethanol and cocaine produced a marked increase in cTnI
levels, which peaked at about 10 h after cocaine administration and
lasted for several hours; a small elevation above background was still
seen at 24 h. This response was abrogated in animals pretreated with
TV-1380, possibly as the result of the noted shift in the metabolic
pathway away from the production of cocaethylene.
4. Discussion
TV-1380 is a rationally mutated, human butyrylcholinesterase en-
zyme (BChE) fused to human serum albumin that was designed as a
long-acting, potent cocaine hydrolytic enzyme. Considering its poten-
tial use as a chronic medication for cocaine dependence, it was essential
to investigate the safety of TV-1380 in monkeys in a repeat dose study
and examine its eﬀect on cocaine metabolism. The results of the 13-
week repeat dose toxicity study, presented here, demonstrate the fa-
vorable safety proﬁle of TV-1380 (up to 50mg/kg/twice a week)
showing tolerability and lack of any treatment related eﬀect. All tested
safety parameters were unaﬀected by TV-1380 treatment including
cardiovascular and respiratory endpoints.
The protective eﬀect of TV-1380 from cocaine induced toxicity was
previously tested in rats and was reported (Brimijoin et al., 2008). Here
we examined the protective eﬀect of TV1380 in monkeys in the pre-
sence of the cocaine, and focused on cocaine-induced changes in car-
diodynamic parameters. The dose of cocaine selected for this study was
1mg/kg, a dose that is not associated with severe CNS signs. While the
administration of intravenous injection of cocaine alone (1mg/kg) re-
sulted in an increase in body temperature, and a small transient rise in
blood pressure and heart rate (beyond the stress response to the in-
jection itself), pre-treatment with TV-1380 (15mg/kg) 3 h prior to co-
caine administration attenuated these eﬀects. The eﬀects noted in this
study for cocaine at 1mg/kg are mild, but consistent with the known
pressor response of the molecule (Gao and Brimijoin, 2004). It is worth
noting that overt cocaine cardiotoxicity in animals is mainly seen at
doses higher than those employed in our study (Hearn et al., 1991).
Fig. 5. Plasma concentrations in male monkeys after IM administration of TV-1380, oral ethanol and IV cocaine. Time-dependent mean (SE) concentrations of
cocaine (A) cocaethylene. (B) benzoylecognine (C) and ecgonine methyl ester (D).
Fig. 6. Plasma concentrations of cardiac Troponin I (cTnI) concentration in
male monkeys. Mean (SE) cardiac troponin I (cTnI) concentration for monkeys
given IM administration of TV-1380, oral ethanol and IV cocaine.
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Investigations of the cocaine clearance in the monkeys have con-
ﬁrmed our previous observations in rats; TV-1380 accelerates the
clearance of cocaine in a dose and time dependent manner.
Pretreatment with TV-1380 was most eﬀective when given a few hours
before cocaine administration, but a clear eﬀect could still be seen at
48 h. Eﬀect was also dependent on the dose of TV-1380; 5mg/kg in-
hibited the exposure to cocaine by more than 75% (when given 2 h
before cocaine), a dose of 1mg/kg produced about 50% inhibition and
the dose of 0.2 mg/kg did not cause a statistically signiﬁcant change.
hBChE primarily eliminates cocaine by hydrolysis to the two known
cocaine metabolites: ecgonine methyl ester and benzoic acid, which are
considered non-toxic (Xie et al., 1999). TV1380 was shown in our
studies to dramatically change the metabolic proﬁle of cocaine in
monkeys by shifting the metabolic clearance away from liver carbox-
ypeptidase towards the BChE-dependent pathway, thereby decreasing
exposure to benzoylecgonine while increasing the exposure to the BChE
metabolite, ecgonine methyl ester. These results are consistent across
species (Schlindler et al., 2013) and seen also in treated humans (Shram
et al., 2015).
The concurrent use of alcohol and cocaine is a common practice
among drug abusers, as it enhances the euphoric eﬀect and reduces
some of the unpleasant late eﬀects of cocaine. However, the combina-
tion of cocaine and alcohol also results in the formation of the active
and toxic metabolite cocaethylene, the ethyl ester of cocaine (Andrews,
1997; Parker and Laizure, 2010). Cocaethylene is more potent than
cocaine in mediating lethality in mice (Hearn et al., 1991) and the
combined use of cocaine and ethanol may present a greater health risk
than cocaine alone (Andrews, 1997).
Our studies indicate that formation of cocaethylene as a metabolite
of cocaine in the presence of ethanol in monkeys is markedly inhibited
when the monkeys are pretreated with TV1380. This eﬀect occurred
concomitantly with the induced decrease in the levels of benzoyleco-
gonine and with the increase in the levels of ecogonine methyl ester, all
indicative of the shift in the metabolic pathway away from that de-
pendent on liver carboxypeptidase. The data also indicate that the
generation of cocaethylene is dependent on the carboxpepditase
mediated hydrolysis. This observation is consistent with earlier pub-
lication on cocaethylene metabolism, showing its dependence on car-
boxypeptidase activity (Brzezinski et al., 1997).
Our results have also demonstrated a marked increase in the levels
of plasma cardiac troponin I (cTnI) in monkeys treated concomitantly
with ethanol and cocaine. cTnI is one of the newest and most speciﬁc
markers of cardiac injury and its enhanced levels in these monkeys may
be related to the generation of cocaethylene. Since this metabolite is
associated with general toxicity and particularly cardiotoxicity, the
elevation of cTnI levels in the treated animals and the inhibition of its
formation by TV-1380 may have important beneﬁcial therapeutic ac-
tivities.
Our in-vitro enzymatic studies with isolated enzymes in human
plasma suggest that TV1380 has a much greater hydrolytic activity than
wild type BChE towards cocaethylene as a substrate (supported by Hou
et al., 2014). Such high catalytic activity can potentially lead to the
rapid removal of cocaethylene from the circulation, as was demon-
strated in vivo in monkeys.
This eﬀect of TV-1380 on the accelerated catabolism of cocaethy-
lene is in addition to the eﬀect of TV-1380 on the formation of co-
caethylene, through the shift in the metabolic pathway away of the
endogenous carboxypeptidase (hCE1) mediated hydrolysis. The two
mechanisms are not mutually exclusive and act in concert to reduce the
levels of cocaethylene in plasma. These data suggest that TV-1380 can
be eﬀective in the treatment of cocaine overdose, not only because it
accelerates the catabolism of cocaine, but also as it reduces the for-
mation of cocaethylene, an active toxic metabolite, and possibly also
accelerates the degradation of this toxic metabolite.
The results presented in this article reveal a promising safety proﬁle
of TV-1380 in treated monkeys, in addition to a potential advantage for
TV-1380 in the reduction of the toxic metabolite, cocaethylene, and the
favorable eﬀects on markers of cardiac damage. These eﬀects should
encourage renewed eﬀorts of pharmaceutical companies to develop
new modiﬁed BChE enzyme products that will have the needed cata-
bolic activity for cocaine and cocaethylene and eventually help in the
treatment of cocaine addiction.
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